Elicio Therapeutics, Inc. (ELTX) — Financial statements
Income statement, balance sheet, and cash flow for Elicio Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 28 | |
| Cost of Revenue | 1↓4.2% | 1↑0.7% | 1↑10.7% | 1↓14.3% | 1 | |
| Gross Profit | -1↑4.2% | -1↓0.7% | -1↓10.7% | -1↓103.9% | 27 | |
| Operating Expenses | ||||||
| R&D Expenses | 25↓26.0% | 34↑48.4% | 23↑33.0% | 17↓64.9% | 49 | |
| General & Administrative Expenses | 13↑13.1% | 11↓4.8% | 12 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 13↑13.1% | 11↓4.8% | 12↑111.3% | 6↓68.3% | 18 | |
| Other Expenses | -1↑4.2% | -1 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 37↓16.5% | 44↑26.7% | 35↑52.5% | 23↓65.8% | 66 | |
| Total Costs & Expenses | 38↓16.2% | 45↑25.9% | 36↑50.6% | 24↓64.9% | 68 | |
| Operating Results | ||||||
| Operating Income | -38↑16.2% | -45↓25.9% | -36↓50.6% | -24↑39.6% | -39 | |
| Depreciation & Amortization | 1↓4.2% | 1↑0.7% | 1↑10.7% | 1↑32.0% | 0.80 | |
| EBITDA | -37↑27.2% | -50↓52.5% | -33↓40.0% | -24↑54.6% | -52 | |
| EBIT | -38↑26.7% | -51↓50.7% | -34↓38.7% | -25↑53.3% | -53 | |
| Interest & Other Income | ||||||
| Net Interest Income | -0.36↓210.9% | 0.32↑146.9% | -0.69↑80.6% | -4↓304.4% | -0.87 | |
| Interest Income | 0.78↓0.1% | 0.78↑108.3% | 0.37↑475.4% | 0.06↑1811.2% | 0.00 | |
| Interest Expense | 1↑149.0% | 0.46↓57.0% | 1↓70.5% | 4↑310.3% | 0.88 | |
| Non-Operating Income | 0.00↓100.0% | 6↑501.3% | -2↓283.3% | 0.88↓93.5% | 13 | |
| Other Income / Expenses | -2↑73.1% | -7↓1356.7% | 0.55↑112.3% | -4↑70.7% | -15 | |
| Income Before Tax | -40↑23.8% | -52↓47.5% | -35↓24.8% | -28↑48.3% | -55 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -40↑23.8% | -52↓47.5% | -35↓24.8% | -28↑48.3% | -55 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -40↑23.8% | -52↓47.5% | -35↓24.8% | -28↓6.8% | -26 | |
| Bottom-Line Net Income | -40↑23.8% | -52↓47.5% | -35↓24.8% | -28↑48.3% | -55 | |
| EPS (Basic) | -2.58↑39.3% | -4.25↑38.9% | -6.96↑23.5% | -9.10↑52.9% | -19.32 | |
| EPS (Diluted) | -2.58↑39.3% | -4.25↑38.9% | -6.96↑23.5% | -9.10↑52.9% | -19.32 | |
| Weighted Average Shares | 15↑25.5% | 12↑141.3% | 5↑63.1% | 3↓3.1% | 3 | |
| Weighted Average Diluted Shares | 15↑25.5% | 12↑141.3% | 5↑63.1% | 3↓3.1% | 3 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.